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Background: Clostridium difficile infection (CDI) is a leading cause of diarrhoea in health care settings with
symptoms ranging from mild and self-limiting to life threatening. SMT19969 is a novel, non-absorbable antibiotic
currently under development for the treatment of CDI. Here we report the results from a Phase I study.
Methods: A double-blind, randomized, placebo-controlled study assessing safety and tolerability of single and
multiple oral doses of SMT19969 in healthy volunteers. Pharmacokinetic assessments included blood and faecal
sampling. The effect of food on systemic exposure and analysis of the gut microbiota were also included.
Results: Fifty-six healthy male subjects were enrolled. Following single oral doses of up to 2,000 mg in the fasted
state, plasma concentrations of SMT19969 were generally below the lower limit of quantification. In the fed state
levels ranged from 0.102 to 0.296 ng/mL after single dosing and after repeat dosing at Day 10 from 0.105 to
0.305 ng/mL. Following single and multiple oral doses of SMT19969, mean daily faecal concentrations increased
with increasing dose level and were significantly above the typical MIC range for C. difficile (0.06-0.5 μg/mL). At
200 mg BID, mean (± SD) faecal concentrations of 1,466 (±547) μg/g and 1,364 (±446) μg/g were determined on
days 5 and 10 of dosing respectively. No notable metabolites were detected in faeces. Overall, all doses of
SMT19969 were well tolerated both as single oral doses or BID oral doses for 10 days. The majority (88%) of adverse
events (AEs) were classified as gastrointestinal disorders and were mild in severity, resolving without treatment. The
gut microbiota was analysed in the multiple dose groups with minimal changes observed in the bacterial groups
analysed except for total clostridia which were reduced to below the limit of detection by day 4 of dosing.
Conclusions: Oral administration of SMT19969 was considered safe and well tolerated and was associated with
negligible plasma concentrations after single and multiple doses. In addition, minimal disruption of normal gut
microbiota was noted, confirming the highly selective spectrum of the compound. These results support the
further clinical development of SMT19969 as an oral therapy for CDI.
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Table 1 Summary of dosing and group design for Parts 1
and 2 of the study








1 A (4) 3:1 2 mg Single Fasted 101 to 104
B (4) 3:1 20 mg Single Fasted 105 to 108
C (8) 6:2 100 mg Single Fasted 109 to 116
D (8) 6:2 400 mg Single Fasted 117 to 124
E TP1 (8) 6:2 1,000 mg Single Fasted 125 to 132
E TP2 (8) 6:2 1,000 mg Single Fed 125 to 132
F (8) 6:2 2,000 mg Single Fasted 133 to 140
2 G (8) 6:2 200 mg BID Fed 201 to 208
H (8) 6:2 500 mg BID Fed 209 to 216
Abbreviations: BID twice daily, N number of subjects studied, TP treatment period.
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Clostridium difficile infection (CDI) is a leading cause of
diarrhoea particularly in hospitals and other health care
settings. The disease is primarily associated with prior
antibiotic use causing a disruption to normal gut micro-
biota allowing C. difficile to proliferate [1], with symptoms
ranging from mild self-limiting diarrhoea to more serious
manifestations including pseudomembranous colitis, toxic
megacolon, bowel perforation, sepsis, and death [2].
Recent years have seen a rise in the severity and incidence
of CDI [3], which is partly due to the emergence of hyper-
virulent strains of the bacteria such as the BI/NAP1/027
strain [4]. A particular concern is recurrence of infection
which occurs in approximately 25% of patients [5], with
each recurrent episode associated with increased risk of
further recurrence and disease severity [6].
Until recently treatment options for CDI were mainly
limited to oral metronidazole and vancomycin, neither
of which are optimal particularly in the treatment of
recurrent infections [7]. Both agents can cause further
disruption to the gut microbiota during therapy, which
may promote recurrent episodes of CDI [8,9]. Vancomycin
achieves faecal concentrations sufficient to inhibit even
Gram-negative organisms, such as Bacteroides fragilis [10].
Metronidazole is highly absorbed from the gastrointestinal
tract and has a spectrum of activity encompassing normal
anaerobic bowel microbiota [11,12]. In addition, C. difficile
isolates with reduced susceptibility to metronidazole have
been reported [13], and both agents are associated with ac-
quisition or overgrowth of organisms such as vancomycin-
resistant enterococci (VRE) [14]. Fidaxomicin, a minimally
absorbed macrocyclic antibiotic with a narrower spectrum
of activity, has recently been approved in the United States
and Europe, and extends the treatment options for CDI
[15,16]. However, additional antibiotics are still needed
that reduce rates of recurrent disease, particularly those
associated with infection due to hyper-virulent strains,
and to preserve use of vancomycin for the treatment of
serious systemic Gram-positive infections.
SMT19969 (2, 2′ bis(4-pyridyl) 3H, 3′H 5,5′ bibenzimida-
zole) is a novel antibiotic currently under development for
the treatment of CDI. In vitro studies have reported C.
difficile MIC90 values of 0.125 μg/mL and 0.25 μg/mL
[17,18]. SMT19969 displays targeted activity against C.
difficile with little or no activity against both Gram-
negative and most Gram-positive aerobes and anaerobes
[17]. Preclinical animal studies have reported negligible
systemic exposure and a favourable safety profile [19].
In the hamster model of CDI, oral administration of
SMT19969 has been shown to be superior to vancomycin,
conferring significant protection from initial infection and
recurrent disease [20].
The objective of the study described here was to assess
the safety, tolerability and pharmacokinetics of SMT19969in healthy volunteers following single and multiple oral
doses. In addition, faecal samples were analysed for
changes in gut microbiota composition following repeat
oral administration.Methods
Study drugs
The Active Pharmaceutical Ingredient (API) was manufac-
tured according to Good Manufacturing Practices and
supplied by Cambridge Major Laboratories (Weert,
Netherlands) along with batch numbers, TSE statements
and Certificates of Analysis. Covance (Leeds, UK) supplied
the appropriate grade of diluent (water) and the placebo
(magnesium hydroxide carbonate). Investigational Medicinal
Product (IMP) was prepared in bottles as a 30 mL
suspension containing the appropriate weight of SMT19969
or magnesium hydroxide carbonate and stored at room
temperature. In order to maintain the blinded status of the
study the placebo suspension was identical in appearance to
the SMT19969 suspension.Design and objectives
The study was conducted in a Clinical Research Unit
(CRU) by Covance CRU Ltd (Leeds, UK) who also per-
formed the PK analysis and reporting. Clinical laboratory
evaluations were performed by Covance Clinical Pathology
Services (Harrogate, UK). Gut microbiome analysis was
performed at Microbiology Department, Leeds Teaching
Hospitals & University of Leeds (Leeds, UK).
With the exception of Group A, which was conducted
single blind, the study was conducted as a double-blind,
randomized, placebo-controlled study in two parts. Part 1
comprised of -ascending single oral doses and a food effect
evaluation and Part 2 consisted of two different twice-daily
oral doses (Table 1). Oral doses were chosen for both
parts of the study, as this is the intended route of
clinical administration.
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tolerability of ascending single and multiple oral doses
of SMT19969 in healthy male subjects. Safety and toler-
ability were assessed through adverse event monitoring and
clinical laboratory evaluations as described below. The
secondary objectives were to determine the single and
multiple oral dose PK of SMT19969, to assess the
effect of food on the systemic exposure of SMT19969, to
assess the effect of multiple oral doses of SMT19969 on
gut microbiota (via assessment of faecal samples) and to
determine concentrations of SMT19969 in faecal samples.
In addition, exploratory work was carried out on selected
faecal samples to look for potential metabolites of
SMT19969. Sampling time points and methodology
for secondary objectives are described below.
Part 1
Forty male subjects were studied in six groups (A to F)
with each group receiving a single ascending oral dose
of SMT19969 or placebo. Groups A and B consisted of
four subjects (three receiving SMT19969 and one pla-
cebo), while each of Groups C to F had eight subjects
with six receiving SMT19969 and two given placebo.
Each subject in Groups A to D and Group F participated
in one treatment period (TP) only whilst subjects in
Group E (food effect) participated in two treatment
periods. Subjects were required to be in residency from
Day −1 (the day prior to first dose administration) and to re-
main for not less than 72 hours after each dosing occasion,
apart from Group E TP2 in which subjects were required to
remain resident until 24 hours post dose (Day 2). There was
a minimum of at least 7 days between completion of dosing
in one group and start of dosing in the next group to allow
a satisfactory review of the safety and PK data from lower
dose levels prior to progression to the next higher dose level
[21]. Six single oral dose levels of SMT19969 (2 to
2000 mg) or placebo were studied (Table 1).
In Part 1, the dose was administrated following an
overnight fast on the morning of Day 1 except Group E
TP 2, with dosing occurring 30 minutes after a high-fat
breakfast [total energy content 895 Kcal; total fat content
61 g (61% of total calories); total protein 41 g (18% of total
calories); total carbohydrate 46 g (19% of total calories)] on
the morning of Day 1. Group E subjects received the same
treatment (single oral dose of SMT19969 or placebo) in
both TPs. All subjects in Part 1 returned for a post study
visit 5 to 7 days after their final dose for the following safety
assessments: Adverse event recording, blood pressure and
pulse rate, oral body temperature, 12 lead ECG, clinical
laboratory evaluations and physical examination.
Part 2
Sixteen male subjects were randomized to two groups
(G and H). In each group six subjects received SMT19969and two were given placebo. Subjects were required to be
in residency 2 days before first dose administration (Day
−2) and to remain until Day 12 (48 hours post final dose).
Two oral dose levels of 200 and 500 mg BID of
SMT19969 or placebo were studied in Groups G and H
respectively (Table 1). For Part 2, subjects received a twice
daily (BID) oral dose of SMT19969 or placebo from Days
1 to 9 (12 hour interval), and a final single oral dose on
the morning of Day 10. The morning doses were given
30 minutes after a light breakfast and the second daily
doses were administered 50 minutes following an evening
meal. All subjects in Part 2 returned for a post-study visit
5 to 7 days post final dose for the following safety
assessments: Adverse event recording, blood pressure and
pulse rate, oral body temperature, 12 lead ECG, clinical
laboratory evaluations and physical examination.
Study subjects
Inclusion criteria were that subjects were healthy males
between 18 and 55 years of age with a body mass index
(BMI) between 18.0 and 32 kg/m2. Subjects were
excluded if they or their partners were unwilling to use
appropriate contraception, or had received any pre-
scribed systemic or topical medication within 14 days, or
had used any non-prescribed systemic medication within
7 days (with the exception of paracetamol ≤2 g/day), or
herbal supplements within 28 days. Subjects were also
excluded if they had irregular bowel habits or had a
positive faecal occult blood (FOB) at Screening and
Day −1 (Groups C to F) or Screening and Day −2
(Part 2). Further exclusion criteria included cardiovascular
disease, alcohol consumption >28 units per week, tobacco
consumption >15 cigarettes per day or a clinically signifi-
cant illness within 4 weeks of enrolment. All subjects
underwent study-specific screening within 28 days prior
to the first dose administration. Informed consent was
obtained from all participants. Subject’s race was recorded
as either American Indian or Alaska Native, Asian, Black,
Native Hawaiian or Other Pacific Islander, White or
Other. Where the race identify was recorded as Other,
then additional specific information was noted.
Randomisation and blinding
The treatment randomisation was produced by the
Statistics Department at Covance CRU using a computer-
generated pseudo-random permutation procedure. Two
subjects were randomly assigned to receive placebo for
Groups B-H whereas for Group A sentinel dosing was
used. Subjects were dosed in numerical order according to
the treatment randomisation. Subjects were enrolled by
blinded clinical staff, whilst subjects were assigned to
interventions by unblind pharmacy staff who prepared the
unit doses for the subjects and kept a copy of the master
treatment randomisation. Unit doses were given to the
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Investigator, clinical staff and data management staff
remained blinded until database lock. To enable the
Investigator to break the code, if required for safety
reasons, individual sealed envelopes containing the
treatment code for each subject were kept in the
Covance CRU pharmacy. If it was necessary to break
the code during the study, the date, time and reason
would have been recorded in the subject’s source data
and on the individual envelope.
Pharmacokinetic assessments
Blood and faecal sampling
Approximately 2 mL of blood was collected at specific
time points for each subject for quantification of
SMT19969. In Part 1 blood was collected pre-dose and
at 1, 2, 4, 8, 12 and 24 hours post-dose. In Part 2 blood
was collected on Day 1 pre-am dose and at 2, 4, 8 and
12 hours post dose; Days 2 to 9 pre-am dose and Day 10
pre-dose and at 1, 2, 4, 8, 12, 24 and 48 hours post dose.
The following pharmacokinetic (PK) parameters were
determined: area under the plasma concentration-time
curve from time zero up to the last quantifiable concentra-
tion (AUC0-tlast), maximum observed plasma concentration
(Cmax), time of maximum observed plasma concentration
(tmax). Pharmacokinetic parameters were determined using
non-compartmental procedures and actual sampling times
post dose used in the computation of PK parameters.
Lower limit of quantification (LLOQ) was defined as
0.1 ng/mL. Due to the low levels and limited number of
samples in which SMT19969 was detected, PK analysis
conducted on ‘worst case’ scenario with plasma concentra-
tions below the limit of quantification (BLQ) from the time
of pre-dose sampling (t = 0) up to the time of the first quan-
tifiable concentration set to a value of zero. The first BLQ
value after a quantifiable level was replaced with the value
of LLOQ (0.1 ng/mL). After this time point, BLQ plasma
concentrations were set to zero. In Part 1 Groups C to F,
faecal samples voided 0–72 hours post dose were pooled
each 24-hour interval and analysed for concentration of
SMT19969. During Part 2, all faecal samples voided whilst
resident in the CRU were collected and stored in a freezer
within 15 minutes of voiding pending analysis. Analysis
of faecal and plasma samples was performed by CLE
(Harrogate UK). Concentrations of SMT19969 in plasma
samples were determined by liquid chromatography with
tandem mass spectrometric detection (LC-MS/MS)
following sample preparation by protein precipitation and
on-line solid phase extraction. Faecal samples were homo-
genised (1:19 faeces: water/acetonitrile/methanesulfonic
acid [60:40:1 v/v/v]) with concentrations of SMT19969
determined by LC-MS/MS. The faecal LLOQ was 20 μg/g.
Day 5 and Day 10 faecal samples from three subjects
in Group G and three pre-dose samples from Group C(as a negative control) were analysed for the presence of
metabolites using accurate mass LC-MS (Thermo LTQ
Orbitrap mass spectrometer). Data were interrogated for
the presence of metabolites based on accurate masses of
potential metabolites using Metworks software (version
1.2) in conjunction with Xcalibur 2.0.7.
Gut microbiota analysis
Pharmacodynamic measurements were performed on
faecal samples in Part 2. Aliquots of the first faecal
sample of the day voided on Days −1, 4 and 9 were
stored at -70°C pending analysis of gut microbiota. All
anaerobic culture and manipulations were performed in
an Anaerobic Workstation (Don Whitley Scientific,
Shipley, UK) at 37°C. A portion of each faecal sample (1 g)
was diluted in 10 ml pre-reduced PBS to produce a 10%
w/v faecal slurry.
For enumeration of C. difficile spores a 2 ml aliquot
was removed which was treated with an equal volume of
96% ethanol and left for 1 h at room temperature. The
alcohol shocked suspension was then 10-fold serially
diluted to 10−8 in pre-reduced peptone water (Sigma
Aldrich, UK). 20 μl of each dilution was used to inoculate
CCEYL plates [Brazier’s CCEY agar, (Bioconnections,
Leeds, UK) supplemented with 5 mg/L lysozyme and 2%
lysed horse blood] in triplicate. Plates were incubated
anaerobically for 48 h and single colonies were counted.
For enumeration of bacteroides, bifidiobacteria, lactoba-
cilli, total clostridia, C. difficile, total anaerobes, lactose-
fermenting enterobacteriaceae (LFE), enterococci and total
aerobes an aliquot of each sample (500 μl) was serially
diluted in 4.5 ml of pre-reduced peptone water to a
dilution of 10−9 in an anaerobic cabinet. Selective agars as
previously described [22] were inoculated in triplicate with
20 μl of each appropriate dilution. After incubation,
colonies were counted and identified on the basis of colony
morphology, colony fluorescence, Gram stain and biochem-
ical reactivity. The limit of detection was 50 cfu/mL.
Safety and tolerability assessments
Adverse events
Any adverse events or remedial actions were recorded in
the subject’s electronic CRF (eCRF) and coded using
Medical Dictionary for Regulatory Activities Version
16.0 terminology. The nature, time of onset, duration and
severity were documented, together with the Investigator’s
opinion of the relationship to drug administration.
Vital signs
Supine blood pressure, supine pulse rate and oral
body temperature were measured at specified times
and also performed at other times if judged to be clinically
appropriate.
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At specified specific times during the study and when
judged to be clinically appropriate, a 12-lead resting elec-
trocardiogram (ECG) with a 10-second rhythm strip was
taken after the subject was supine for at least 5 minutes.
Clinical laboratory evaluations
Blood and urine were collected for the following laboratory
evaluations; serum biochemistry, haematology, serology
(Hepatitis B surface antigen, Hepatitis C antibody, HIV),
drug and alcohol screen and urinalysis.
Faecal occult blood (FOB)
FOB (hema-screen, Alpha Labs, Eastleigh, UK) assessment
was conducted on samples collected at screening and
voided 48–72 hours post dose. Whilst in residence, all
faecal samples were also visually assessed for consistency
in accordance with the Bristol Stool Chart [23].
Statistical analysis
The analysis population consisted of all subjects who
received one or more doses of study drug. No formal
statistical assessment of sample size was conducted,
as this was the first time SMT19969 had been administered
to man. However, the number of subjects who participated
in this study is common in early clinical pharmacology
studies and was considered sufficient to achieve the objec-
tives of the study. No inferential statistical analyses were
performed for PK.
The study was carried out in compliance with the
Helsinki Declaration (http://www.wma.net/en/30publica-
tions/10policies/b3/index.html website). Ethical approval
was received on 20/09/2012 (reference number 12/
EE0362) from the National Research Ethics Service
(NRES) Committee East of England.
Results
A total of 56 subjects were randomized (Figure 1) and
entered the study, with 40 subjects in Part 1, and 16
subjects in Part 2. The study started on 8th October 2012
(date of first informed consent) and was completed on 8th
April 2013 once all subjects had been dosed and the final
post study observation had been carried out. In Part 1, all
subjects were men with a mean age of 32 years (range 18
to 53 years), a mean weight of 79.8 kg (range 54.7 to
99.2 kg), mean height of 178 cm (range 166 to 194 cm)
and a mean BMI of 25.4 kg/m2 (range 19.4 and 31.3 kg/m2).
All subjects were White, except one subject who was
Black, two subjects who were Other: African/Caucasian,
and one subject who was Other: mixed race - Caucasian
and Asian. In Part 2, all subjects were men with a mean
age of 35 years (range 18 to 54 years), a mean weight of
81.7 kg (range 62.8 to 96.0 kg), mean height of 179 cm
(range 168 to 193 cm) and a mean BMI of 25.7 kg/m2(range 18.3 to 30.3 kg/m2). All subjects were White,
except one subject who was Asian. One subject in
Group B was withdrawn from the study due to acute
appendicitis, which commenced on Day 1 and was
not considered due to study drug. A total of 55 subjects
completed the study in accordance with the protocol and
the treatment randomization. All 56 subjects were
included in the safety population.
Safety
Following single oral doses of SMT19969 in Part 1 and
multiple oral doses of SMT19969 in Part 2, there were
no apparent treatment- or dose-related trends in supine
systolic and diastolic blood pressure, pulse rate and oral
body temperature. There were no clinically important
findings in the morphology of the 12-lead ECG for
individual subjects at each single and multiple dose
level of SMT19969. There were no clinically significant
findings in the physical examination performed at Screening
or at post-study. There were no treatment- or dose-related
trends in the serum biochemistry, haematology, or
urinalysis data during the study. All subjects in Part 1
Groups C to F and Part 2 tested negative for occult
blood in post-dose faecal samples. The majority of
faecal samples in both parts of the study were categorized
as type 4 or below on the Bristol Stool Chart. Frequency
and quality of stool was, in the opinion of the investigators,
independent of dose.
Overall, all doses of SMT19969 were well tolerated
when administered as single oral doses or BID oral doses
for 10 days. The majority of AEs considered possibly
related to study drug were classified as gastrointestinal
(GI) disorders and were mild in severity and resolved
without treatment (Table 2). Overall the incidence of
adverse events reported by subjects in both Part 1 and
Part 2 was low and no greater than the incidence of AEs
reported by subjects administered placebo. There was
one serious adverse event (SAE), acute appendicitis, which
led to the subject being discontinued from the study and
was considered unlikely to be related to the study drug.
Pharmacokinetics in plasma
Part 1
Following single oral doses of up to 2,000 mg SMT19969
in the fasted state, plasma concentrations of SMT19969
were generally below the LLOQ of the assay (0.1 ng/mL)
at the majority of blood sampling times. At the 100 and
2,000 mg dose levels, two and one subjects, respectively,
had isolated plasma samples (one to two per subject) with
quantifiable levels of SMT19969 that were close to the
LLOQ of the assay (0.1 ng/mL) and ranged from 0.103 to
0.133 ng/mL. Following a single oral dose of 1,000 mg
SMT19969 in the fed state, SMT19969 was quantified in
the plasma in all six subjects (one to four quantifiable
Figure 1 Study flow diagram.
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ranging from 0.102 to 0.296 ng/mL (Table 3). The time of
maximum observed plasma concentration (Tmax) of
SMT19969 occurred approximately 4 hours post-dose.
Part 2
After repeat administration of SMT19969 in the fed
state with 200 and 500 mg BID doses, parent compoundTable 2 Incidence of adverse events in Groups A to H
Number of subjects with adverse ev
Group and dose of SMT19969
Adverse event A-H A B C D
Placebo 2 mg 20 mg 100 mg 400 mg
(N = 14) (N = 3) (N = 3) (N = 6) (N = 6)
Diarrhoea 3 1 2







Abbreviations: BID twice daily, N Number of subjects studied, TP Treatment period, Bwas quantifiable in the plasma of most subjects by Day
10, although the plasma concentrations were very low,
ranging from 0.105 to 0.305 ng/mL with Tmax occurring
at approximately 4 hours post-dose.
Pharmacokinetic parameters were only calculated from
the groups dosed under fed conditions (Part 1 1,000 mg,
Part 2 200 mg BID and 500 mg BID), as SMT19969 con-
centrations were quantifiable in one or more sampleents considered possible related to study drug
E F G H
1,000 mg 2,000 mg 200 mg BID 500 mg BID







lank cell no AE reported.
Table 3 Summary of pharmacokinetic parameters following administration of SMT19969 in the fed state
Mean (min – max) pharmacokinetic parameters
Group E TP2 Group G Group H
1000 mg 200 mg BID 500 mg BID
Day 1 Day 1 Day 10 Day 1 Day 10
(N = 6) (N = 1) (N = 5) (N = 4) (N = 6)
AUC0-tlast (ng.h/mL) 1.33 (0.706 – 3.46) 0.559 (N/A) 0.670 (0.524 – 1.30) 0.670 (0.531 – 1.23) 1.15 (0.515 – 1.98)
Cmax(ng/mL) 0.211 (0.102 – 0.296) 0.120 (N/A) 0.141 (0.108 – 0.243) 0.148 (0.110 – 0.305) 0.177 (0.105 – 0.279)
Abbreviations: BID twice daily, AUC0-tlast area under the plasma concentration-time curve from time zero up to the last quantifiable concentration, Cmax maximum
observed plasma concentration, N Number of subjects from which SMT19969 concentrations were quantifiable and could be included in calculation of PK parameters.
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exception was the 200 mg BID dose group on Day 1, in
which only one subject had quantifiable concentrations
of SMT19969 although these PK parameters were
reported to enable comparison with Day 10 data. Table 3
summarizes the pharmacokinetic results for those subjects
from which SMT19969 concentrations were quantifiable
and could therefore be included in calculation of PK
parameters.
Following repeat dosing the plasma concentration data
suggest there may be some increase in absorption over
time, with a greater proportion of subjects having quantifi-
able plasma levels of SMT19969 on Day 10, and the num-
ber of quantifiable samples per subject also being greater.
This was suggested by a marginal increase in AUC0-tlast on
Day 10 compared to Day 1, although these data should be
interpreted with care due to the non-standard, worst-case
scenario approach used to derive these PK parameters.
Overall, the systemic exposure of SMT19969 following
oral dosing was minimal with plasma concentrations
no more that approximately three-fold above the limit
of quantification.
Faecal sample analysis
Tables 4 and 5 present the results for faecal concentrations
of SMT19969 determined during the two parts of the study.
Following single and multiple oral doses of SMT19969, the
mean daily faecal concentrations increased with increasing
dose level. Following a single 400 mg dose, group mean
faecal concentrations peaked at 1,132 μg/g 24–48 hours
post dosing and remained high up to 72 hours post dosingTable 4 Faecal concentrations of SMT19969 following single
Group Dose Mean (min – max) fae
Time post dose (hours
0-24
C 100 mg 20 (<20 – 20)
D 400 mg 239 (<20 – 317)
E TP1 1,000 mg 1,194 (<20 – 2,310)
F 2,000 mg <20 (<20 – <20)(group mean = 677 μg/g). Multiple oral doses resulted in
faecal concentrations significantly above the MIC90 of
SMT19969 for C. difficile (0.125 – 0.25 μg/mL) with
Day 10 Group G and H means (±SD) of 1,364 (407.07)
and 3,318 (897.28) μg/mL, respectively.
No notable metabolites were detected in faeces, with
the majority of the administered dose excreted as
unchanged parent drug, which accounted for >97% of the
total peak area. All metabolites detected were individually
present at <0.3% of the total peak area. Table 6 presents
the data for the composition of SMT19969 and metabolites
from three subjects in Group G.
Faecal samples voided pre and during the course of
dosing in Group G and Group H were analysed for
changes in gut microbiota composition. The panel of
bacteria that were assessed were chosen as representative
and reliably culturable Gram positive and Gram negative
members of the endogenous gut microbiota and also to
mimic the bacteria assessed in the human gut model of
CDI [22,24]. Although culture techniques were used in this
study, future studies examining the effect of SMT19969 on
gut microbiota using genomic techniques are warranted.
Overall the data show that repeat oral administration of
SMT19969 caused minimal changes in bacterial counts
(group median data shown in Figures 2 and 3), except for
total clostridia where 3 log10 reductions in counts were
observed in both Group G and H by day 4; clostridial
counts remained below the limit of detection to day 9
(last day of measurement).
In Group G a slight increase was observed in bacteroides




213 (<20 – 330) 210 (<20 – 598)
1,132 (<20 – 3,340) 677 (436 – 948)
855 (305 – 1,040) 1,209 (183 – 1,970)
5713 (<20 – 11,800) 6,478 (1,030 – 17,600)
Table 5 Faecal concentrations of SMT19969 following
multiple oral doses (Part 2)
Group Dose Mean (min – max) Faecal
concentrations (μg/g)
Nominal day of dosing
Day 5 Day 10
G 200 mg twice daily 1,466 (847 – 2,390) 1,364 (783 – 1,980)
H 500 mg twice daily 2,084 (994 – 3,790) 3,318 (2,130 – 4,970)






















Figure 2 Median log10 CFU/mL changes in gut microbiota
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remained constant until day 9). Counts of bifidobacteria
and total anaerobes remained constant with minimal
fluctuations observed. Total aerobe and LFE counts
both remained constant until day 4 and then both increased
(2 log by day 9).
Comparable results were observed in Group H with
SMT19969 having minimal effect on gut microbiota
populations except for total clostridia. Total anaerobe
and bacteroides populations remained constant until
day 4, before decreasing modestly (2 log at day 9);
bifidiobacteria and lactobacilli counts remained constant
throughout. Numbers of total aerobes and LFEs increased
(4 and 2 log, respectively) by day 4 before returning to
baseline levels by day 9.
As part of the microbiota analysis, the quantification
of enterococci was included although, particularly for
Group G, counts were low or below the limit of detection.
In Group H, enterococci were quantified in all pre-dose
samples (median = 3.35 log10 CFU/mL), in half the day 4
samples (median = 1.1 log10 CFU/mL) and all day 9
samples except one (median = 2.7 log10 CFU/mL). In
Group G, enterococci could only be quantified at all three
time-points for one subject and at a single time-point
(either pre-dose or day 4) for two other subjects.
Conclusions on the potential effect of SMT19969 on
enterococci are difficult to draw from these data although
previous susceptibility testing [16] and data from a gut
model of CDI [24] would indicate SMT19969 is associated
with minimal activity against enterococci.
No C. difficile viable cells or spores were detected in
any samples voided either pre-dosing or during the
course of dosing.Table 6 Composition of SMT19969 and metabolites in
faeces of three subjects from Group G
Name % of Total Peak Area
Subject 1 Subject 2 Subject 3
Day 5 Day 10 Day 5 Day 10 Day 5 Day 10
SMT19969 99.05 99.34 99.21 100.00 97.99 97.72
Total metabolites 0.95 0.66 0.79 0.00 2.01 2.28Discussion
CDI remains a significant burden to healthcare systems
and new agents are required that effectively treat initial
infection and reduce rates of recurrent disease. SMT19969
is a novel antimicrobial agent with a highly specific
spectrum of activity that may cause reduced damage to the
gut microbiota during CDI therapy compared with current









Figure 3 Median log10 CFU/mL changes in gut microbiota
composition for all Group H subjects. Abbreviations: LFE = Lactose
fermenting enterobacteriaceae.
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yield lower CDI recurrence rates.
This first in man study was designed to examine
the safety, tolerability and pharmacokinetics of orally
administered SMT19969. Overall, single oral doses of
SMT19969 were considered to be safe and well tolerated
by healthy male subjects when administered at doses
levels of 2, 20, 100, 400, 1,000 and 2,000 mg. In addition,
multiple oral doses of SMT19969 were considered to be
safe and well tolerated by male subjects at dose levels of
200 and 500 mg BID for 9 days with a final dose on Day
10. All AEs considered possibly or likely due to study drug
were mild and no dose dependent relationship between
SMT19969 and incidence or severity of AEs was
noted. No clinically significant findings from blood
pressure, body temperature, 12-lead ECG, clinical
laboratory evaluations (serum biochemistry, urinalysis
and haematology), faecal occult blood or physical
examination were observed.
Oral administration was associated with negligible
systemic exposure. Although this increased following
administration with food, the levels achieved were low
and no more than approximately three fold above the
limit of quantification with the highest recorded Cmax =
0.305 ng/mL. The increase in systemic exposure of
SMT19969 when administered with food is not likely to
be of clinical significance. Following dosing at 200 mg
BID, Day 5 and Day 10, achieved mean (± SD) faecal con-
centrations were 1,466 (±547) μg/g and 1,364 (±446) μg/g,
respectively, which were significantly above the MIC for
C. difficile.
The highly selective spectrum of activity of SMT19969
was confirmed by analysis of faecal samples obtained
following repeat administration of SMT19969. With
the exception of total clostridia, minimal disruption
to the gut microbiota was observed. Notably, bacteroides,
bifidobacteria and lactobacilli, which have been associated
with colonisation resistance, were largely unaffected
[10,25-27]. These data indicate that SMT19969, unlike
vancomycin and metronidazole, may not cause ongoing
collateral damage to the gut microbiota during CDI
therapy, allowing for natural restoration of colonisation
resistance to be initiated during treatment. Such attributes
may be expected to result in reduced rates of recurrent
infection.
Conclusions
In conclusion, this first in man study has shown oral
administration of SMT19969 in healthy volunteers to
be safe and well tolerated, to be associated with negligible
oral bioavailability and to cause minimal disruption to gut
microbiota. These results support continued clinical
development of SMT19969 to further assess safety
and efficacy as an oral therapy for CDI.Competing interests
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